177Lu-LNC1010

177Lu-LNC1010 is a novel radiopharmaceutical developed for peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptor-positive tumors, particularly neuroendocrine tumors (NETs). It represents an advancement over previous somatostatin receptor-targeting radiopharmaceuticals by incorporating an albumin-binding moiety (Evans blue) with a modified linker structure to improve pharmacokinetics and tumor retention. **Mechanism of Action** 177Lu-LNC1010 combines lutetium-177, a beta-emitting radioisotope, with a peptide carrier that specifically targets somatostatin receptors (particularly SSTR2) which are overexpressed in certain tumors. The drug's design includes: 1. A peptide component that mimics somatostatin analogues, allowing preferential binding to SSTR2-positive tumor cells 2. An Evans blue (EB) moiety that enables albumin binding, extending circulation time 3. A modified polyethylene glycol chain replacing the maleimide-thiol group found in earlier versions 4. Lutetium-177 as the therapeutic radioisotope, which emits beta radiation to damage tumor cell DNA Once bound to tumor cells expressing somatostatin receptors, the complex is internalized, allowing the beta radiation to cause localized damage to the tumor cell's DNA, triggering cell death while minimizing damage to surrounding healthy tissues. **Clinical Development** The first-in-human trial of 177Lu-LNC1010 demonstrated promising results: * Well-tolerated safety profile with minor adverse effects * Significant tumor uptake and prolonged retention compared to previous agents * 83% disease control rate and 42% overall response rate after two treatment cycles * Optimal therapeutic dose identified as 3.3 GBq/cycle for future trials The drug is currently being evaluated in clinical trials for patients with advanced SSTR2-positive tumors, particularly gastroenteropancreatic neuroendocrine tumors (GEP-NETs). **Advantages Over Previous Agents** 177Lu-LNC1010 shows several improvements over previous SSTR2-targeting radiopharmaceuticals like 177Lu-DOTATATE (Lutathera): * Enhanced tumor uptake and retention * Improved pharmacokinetics and pharmacodynamics * Better stability in vivo * Higher tumor radiation doses These properties potentially allow for more effective treatment with reduced systemic toxicity compared to earlier generations of radiopharmaceuticals targeting the same receptors.

Other names

177Lu-LNC1010 2[177Lu]Lu-LNC1010Lutetium (177Lu) LNC1010